Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...
The increasing costs and complexity of R&D in the pharmaceutical industry have necessitated the adoption of strategic ...
As global markets grapple with ongoing trade uncertainties and recession fears, major indices like the S&P 500 and Dow Jones Industrial Average have seen consecutive weeks of negative returns. Amidst ...